Cargando…

Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis

AIMS: To analyse the population pharmacokinetics (PK) of peficitinib in patients with rheumatoid arthritis (RA) and assess the potential PK covariates to identify the requirement for dose adjustment in RA patients. METHODS: The analysis incorporated 2464 observations from 98 healthy volunteers and 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toyoshima, Junko, Shibata, Mai, Kaibara, Atsunori, Kaneko, Yuichiro, Izutsu, Hiroyuki, Nishimura, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056739/ https://www.ncbi.nlm.nih.gov/pubmed/33068028 http://dx.doi.org/10.1111/bcp.14605

Ejemplares similares

Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2021)

The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two‐Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects
por: Shibata, Mai, et al.
Publicado: (2020)

A drug–drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Efficacy of peficitinib in two patients with rheumatoid arthritis on maintenance hemodialysis
por: Nishimura, Akito, et al.
Publicado: (2022)

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2020)

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2020)

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib
por: Diller, Magnus, et al.
Publicado: (2019)

Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects
por: Gao, Xin, et al.
Publicado: (2022)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Investigation of Potential Drug–Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis
por: Zhu, Tong, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus
por: Saito, Masako, et al.
Publicado: (2019)

Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
por: Ikari, Yuzo, et al.
Publicado: (2019)

Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma
por: Aoyama, Yumiko, et al.
Publicado: (2012)

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
por: Genovese, Mark C., et al.
Publicado: (2019)

Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus
por: Saito, Masako, et al.
Publicado: (2020)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
por: Oshima, Hiroyuki, et al.
Publicado: (2015)

Population Pharmacokinetics and Exposure‐Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis
por: Li, Xiaohui, et al.
Publicado: (2018)

In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors
por: Kitanaga, Yukihiro, et al.
Publicado: (2020)

Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
por: Chan, Phyllis, et al.
Publicado: (2020)

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
por: Kang, Jia, et al.
Publicado: (2020)

Successful peficitinib addition on anti-MDA5 antibody-positive dermatomyositis refractory to triple therapy and glucocorticoid reduction
por: Oba, Yuki, et al.
Publicado: (2022)

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis
por: Liu, Yong, et al.
Publicado: (2014)

The impact of bDMARDs on postoperative complications in patients with rheumatoid arthritis: A systematic review and meta-analysis
por: Suto, Takahito, et al.
Publicado: (2023)

Population Pharmacokinetics of Fosdagrocorat (PF‐04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis
por: Weatherley, Barry, et al.
Publicado: (2017)

Relationship between disease activity level and physical activity in rheumatoid arthritis using a triaxial accelerometer and self-reported questionnaire
por: Toyoshima, Yoichi, et al.
Publicado: (2021)

Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients
por: Hopkins, AM, et al.
Publicado: (2015)

Rheumatoid arthritis-associated aortitis: a case report and literature review
por: Kaneko, Shunta, et al.
Publicado: (2014)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis
por: Nemoto, Tetsuya, et al.
Publicado: (2020)

Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
por: Xie, Rujia, et al.
Publicado: (2019)

Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit
por: Nonoshita, Ko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_duck2lllvk4re247km3gon37ks